NDAORALELIXIR
Approved
Jan 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXIBOLIN (ethylestrenol) is an oral anabolic steroid elixir approved by Merck & Co. in 1965 for treating conditions requiring anabolic support and protein synthesis enhancement. The drug functions as a synthetic androgen with anabolic properties, historically used in clinical settings before modern alternatives became available.
LOE Approaching
This legacy product is nearing loss of exclusivity with minimal commercial activity, suggesting small team size and limited career growth opportunities within this franchise.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MAXIBOLIN offers extremely limited career opportunities due to its LOE status and minimal market activity. Any roles associated with this product are likely in sunset/legacy management rather than growth or innovation-focused positions.
Brand ManagerField Sales Representative
Worked on MAXIBOLIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.